QUEBEC, April 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ - News; Nasdaq: AEZS - News), a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining first in vitro data on its pyridopyrazine derivatives with high selectivity for PI3K inhibition, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.
